Trial Profile

Phase I trial of a sustained-exposure formulation of gacyclidine (OTO-311) as a potential therapy for tinnitus.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Mar 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gacyclidine (Primary)
Indications Tinnitus
Focus Adverse reactions
Sponsors Otonomy [CEASED]

Most Recent Events

02 Mar 2017 According to an Otonomy media release, status changed from recruiting to completed.
03 Nov 2016 According to an Otonomy media release, several dose cohorts in the trial have been completed without patient tolerability concerns and the trial will remain open into 2017 pending the potential evaluation of additional dose levels in order to establish a maximum tolerated dose.
16 Nov 2015 This trial is expected to be completed in the first half of 2016, according to an Otonomy media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com